Literature DB >> 9241619

Still a role for plasma exchange in rapidly progressive glomerulonephritis?

J B Levy1, C D Pusey.   

Abstract

Plasmapheresis combined with immunosuppression dramatically improved the survival of patients with Goodpasture's disease in the late 1970's. The presence of circulating pathogenic autoantibodies in this disease provided a logical rationale for the use of plasma exchange therapy. Careful analysis of the response to treatment has suggested that patients presenting with a serum creatinine < 600 mumol/I have the most benefit from plasma exchange. Subsequently plasmapheresis has been tried in a variety of other nephritides, predominantly those causing rapidly progressive glomerulonephritis, with variable success. Initial studies failed adequately to distinguish patients with a number of quite distinct causes of crescentic nephritis. However it has become clear that plasma exchange significantly improves the outcome of patients with pauci-immune crescentic glomerulonephritis who present with severe renal failure requiring dialysis, but not those with less severe renal disease.

Entities:  

Mesh:

Year:  1997        PMID: 9241619

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  3 in total

1.  Crescentic glomerulonephritis in a child with infective endocarditis.

Authors:  Banu Sadikoglu; Ilmay Bilge; Isin Kilicaslan; Muge G Gokce; Sevinc Emre; Turkan Ertugrul
Journal:  Pediatr Nephrol       Date:  2006-04-20       Impact factor: 3.714

Review 2.  Acute glomerulonephritis.

Authors:  C S Vinen; D B G Oliveira
Journal:  Postgrad Med J       Date:  2003-04       Impact factor: 2.401

Review 3.  Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan.

Authors:  Kouichi Hirayama; Kunihiro Yamagata; Masaki Kobayashi; Akio Koyama
Journal:  Clin Exp Nephrol       Date:  2008-04-08       Impact factor: 2.801

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.